Gesty-Palmer D - Search Results

1

Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.

Baker C, Wason S, Banks P, Sawhney S, Chang A, Danne T, Gesty-Palmer D, Kushner JA, McGuire DK, Mikell F, O'Neill M, Peters AL, Strumph P. Baker C, et al. Among authors: gesty palmer d. Diabetes Obes Metab. 2019 Nov;21(11):2440-2449. doi: 10.1111/dom.13825. Epub 2019 Aug 1. Diabetes Obes Metab. 2019. PMID: 31264767 Free PMC article. Clinical Trial.

2

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.

Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, Pozzilli P, Gesty-Palmer D, Lapuerta P, Simó R, Danne T, McGuire DK, Kushner JA, Peters A, Strumph P. Garg SK, et al. Among authors: gesty palmer d. N Engl J Med. 2017 Dec 14;377(24):2337-2348. doi: 10.1056/NEJMoa1708337. Epub 2017 Sep 13. N Engl J Med. 2017. PMID: 28899222 Free article. Clinical Trial.

3

Regulator of G protein signaling 5 is highly expressed in parathyroid tumors and inhibits signaling by the calcium-sensing receptor.

Koh J, Dar M, Untch BR, Dixit D, Shi Y, Yang Z, Adam MA, Dressman H, Wang X, Gesty-Palmer D, Marks JR, Spurney R, Druey KM, Olson JA Jr. Koh J, et al. Mol Endocrinol. 2011 May;25(5):867-76. doi: 10.1210/me.2010-0277. Epub 2011 Mar 10. Mol Endocrinol. 2011. PMID: 21393447 Free PMC article.

4

β-arrestin-selective G protein-coupled receptor agonists engender unique biological efficacy in vivo.

Gesty-Palmer D, Yuan L, Martin B, Wood WH 3rd, Lee MH, Janech MG, Tsoi LC, Zheng WJ, Luttrell LM, Maudsley S. Gesty-Palmer D, et al. Mol Endocrinol. 2013 Feb;27(2):296-314. doi: 10.1210/me.2012-1091. Epub 2013 Jan 11. Mol Endocrinol. 2013. PMID: 23315939 Free PMC article.

5

Inhibition of WNT signaling by G protein-coupled receptor (GPCR) kinase 2 (GRK2).

Wang L, Gesty-Palmer D, Fields TA, Spurney RF. Wang L, et al. Mol Endocrinol. 2009 Sep;23(9):1455-65. doi: 10.1210/me.2009-0084. Epub 2009 Jun 25. Mol Endocrinol. 2009. PMID: 19556343 Free PMC article.

6

Refining efficacy: exploiting functional selectivity for drug discovery.

Gesty-Palmer D, Luttrell LM. Gesty-Palmer D, et al. Adv Pharmacol. 2011;62:79-107. doi: 10.1016/B978-0-12-385952-5.00009-9. Adv Pharmacol. 2011. PMID: 21907907 Review.

7

Beyond desensitization: physiological relevance of arrestin-dependent signaling.

Luttrell LM, Gesty-Palmer D. Luttrell LM, et al. Pharmacol Rev. 2010 Jun;62(2):305-30. doi: 10.1124/pr.109.002436. Epub 2010 Apr 28. Pharmacol Rev. 2010. PMID: 20427692 Free PMC article. Review.

8

The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation.

Tohgo A, Choy EW, Gesty-Palmer D, Pierce KL, Laporte S, Oakley RH, Caron MG, Lefkowitz RJ, Luttrell LM. Tohgo A, et al. J Biol Chem. 2003 Feb 21;278(8):6258-67. doi: 10.1074/jbc.M212231200. Epub 2002 Dec 6. J Biol Chem. 2003. PMID: 12473660 Free article.

9

beta-Arrestin 2 expression determines the transcriptional response to lysophosphatidic acid stimulation in murine embryo fibroblasts.

Gesty-Palmer D, El Shewy H, Kohout TA, Luttrell LM. Gesty-Palmer D, et al. J Biol Chem. 2005 Sep 16;280(37):32157-67. doi: 10.1074/jbc.M507460200. Epub 2005 Jul 15. J Biol Chem. 2005. PMID: 16027114 Free article.

10

The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis.

DuSell CD, Nelson ER, Wang X, Abdo J, Mödder UI, Umetani M, Gesty-Palmer D, Javitt NB, Khosla S, McDonnell DP. DuSell CD, et al. Endocrinology. 2010 Aug;151(8):3675-85. doi: 10.1210/en.2010-0080. Epub 2010 May 25. Endocrinology. 2010. PMID: 20501668 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

32 results

Search Page